Company intelligence / Profile preview
FUTRUE
Munich*, Bavaria*, Germanyfutrue.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
FUTRUE has developed innovative therapies such as the cannabinoid-based pain medication VER‑01, which represents a significant milestone toward treating chronic pain. The company also launched Kijimea for irritable bowel syndrome, now a market leader. Their R&D arm aims to halve clinical trial times and costs compared to industry standards
- Therapeutic areas
- GastroenterologyNeurology
- Modalities
- Small moleculeBiologic (including cannabinoid-based drugs, probiotics)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Not explicitly listed; focus appears on internal innovation and subsidiary structure.
Beyond the preview
Go deeper on FUTRUE.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FUTRUE.